Opinion
Video
The Future of IV and Subcutaneous Therapies in Oncology
Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and collaboration drive the growing integration of SubQ formulations as a convenient and adaptable option in cancer care.
As more SubQ formulations enter the oncology market, their presence is expected to grow significantly across various cancer types and treatment modalities. However, it is unlikely that IV infusions will become obsolete. Instead, a balanced coexistence of both delivery methods is anticipated, with the choice depending on patient-specific factors such as disease type, lifestyle preferences, prior treatment experiences, and tolerance to toxicities. Some patients may favor SubQ for its convenience, while others may still require or prefer IV administration. This complementary relationship will help tailor therapies to individual patient needs and clinical circumstances.
Looking ahead, the integration of SubQ therapies into oncology care will likely continue to evolve, driven by ongoing innovation and collaboration across health care providers, manufacturers, and payers. There is optimism about the potential for more complex SubQ formulations, including combinations of drugs delivered in a single injection, which could simplify treatment and reduce burdens on health care facilities. This innovation could also lessen the need for specialized infrastructure, such as clean rooms, potentially lowering costs and expanding access. The oncology landscape is rapidly changing, and flexibility will be key to adapting to new therapeutic options and patient expectations.
Ultimately, SubQ formulations are expected to become a mainstay in oncology practice over the next several years, driven in part by younger generations who will seek faster, more convenient treatment options. Practices that embrace these changes through education, collaboration, and patient-centered care will be better positioned to meet evolving demands and improve outcomes. While the pace of change may be gradual, the momentum toward broader adoption of SubQ therapies is clear, marking an exciting future for oncology treatment administration.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
